Request Appointment
1275 York AvenueNew York, NY 10065
Overview of Dr. Modak
Dr. Shakeel Modak is a pediatric hematologist/oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center and New York-Presbyterian Hospital. He received his medical degree from Topiwala National Medical College and has been in practice 38 years. He is one of 107 doctors at Memorial Sloan Kettering Cancer Center and one of 133 doctors at New York-Presbyterian Hospital who specialize in Pediatric Hematology & Oncology. He has more than 100 publications and over 500 citings.
Education & Training
New York Presbyterian Hospital (Cornell Campus)Fellowship, Pediatric Hematology/Oncology, 1996 - 1999
Central Iowa Health System (Iowa Methodist Medical Center)Residency, Pediatrics, 1995 - 1996
Topiwala National Medical CollegeClass of 1988
Certifications & Licensure
NY State Medical License 2001 - 2027
IA State Medical License 1995 - 1996
American Board of Pediatrics Pediatric Hematology-Oncology
Awards, Honors, & Recognition
- New York Magazine: Top Doctors Castle Connolly, 2014-2020
Clinical Trials
- Beta-Glucan and Rituximab in Treating Young Patients With Relapsed or Progressive Lymphoma or Leukemia, or Lymphoproliferative Disorder Related to Donor Stem Cell Transplantation Start of enrollment: 2004 May 01
- Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- Iodine I 131 Monoclonal Antibody 3F8 and Bevacizumab in Treating Patients With Relapsed or Refractory Neuroblastoma Start of enrollment: 2006 Aug 01
Publications & Presentations
PubMed
- 1 citationsEarly Detection of Neuroblastoma Recurrence on 18 F m FBG PET.Neeta Pandit-Taskar, Anita Price, Gerald Behr, Arnold F Jacobson, Shakeel Modak
Clinical Nuclear Medicine. 2026-07-01 - A phase II trial of naxitamab plus stepped-up dosing of GM-CSF for patients with high-risk neuroblastoma in second or later complete remission.Brian H Kushner, Shakeel Modak, Charlie White, Ellen M Basu, Stephen S Roberts
International Journal of Cancer. 2026-06-15 - Low-Dose Intravenous Ketamine for Primary Pain Control During Naxitamab Anti-GD2 Immunotherapy Treatment.Rosanna Silber, Benjamin Record, Nicole Fernandez, Julienne Szabo, Emily Hahn
Pediatric Blood & Cancer. 2026-06-01
Press Mentions
- Y-mAbs Announces Naxitamab Chemoimmunotherapy Investigational Trial for High-Risk Neuroblastoma Meets Primary EndpointMay 26th, 2022
- Y-mAbs to Host Key Opinion Leader Webinar on DANYELZA® (Naxitamab-Gqgk) Frontline and HITS Data in High-Risk NeuroblastomaSeptember 10th, 2021
Y-mAbs to Host Virtual Research & Development Day on Wednesday, December 16December 7th, 2020
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
